Treatment of established postmenopausal osteoporosis with raloxifene: A randomized

被引:190
作者
Lufkin, EG
Whitaker, MD
Nickelsen, T
Argueta, R
Caplan, RH
Knickerbocker, RK
Riggs, BL
机构
[1] Mayo Clin, Div Endocrinol & Metab, Rochester, MN 55905 USA
[2] Mayo Clin, Div Endocrinol, Scottsdale, AZ USA
[3] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
[4] Gundersen Clin Ltd, Endocrinol Sect, La Crosse, WI USA
关键词
D O I
10.1359/jbmr.1998.13.11.1747
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Raloxifene is a selective estrogen receptor modulator that in experimental animals acts as an estrogen receptor antagonist in breast and endometrium but as an estrogen receptor agonist in the skeletal and cardiovascular systems. We conducted a 1-year prospective, randomized, double-blind trial in 143 postmenopausal osteoporotic women (mean +/- SD age, 68.4 +/- 5.0 years) with at least one prevalent vertebral fractures and low bone mineral density (BMD), comparing groups receiving raloxifene at 60 mg/day (RLX60) or 120 mg/day (RLX120) and a control group receiving supplements of 750 mg/day of calcium and 400 IU/day of vitamin D, There were no differences among groups in the occurrence of uterine bleeding thrombophlebitis, breast abnormalities, or increased endometrial thickness (assessed by ultrasonography), As compared with controls, the changes in values over 1 year for RLX60 and RLX120, respectively, were significant for serum bone alkaline phosphatase (-14.9%, -8.87%), serum osteocalcin (-20.7%, -17.0%), and urinary C-telopeptide fragment of type I collagen/creatinine (-24.9%, -30.8%), markers of bone turnover; for serum total cholesterol (-7.0% for RLX60) and low density lipoprotein cholesterol (LDL) (-11.4% for RLX60) and for the LDL/HDL cholesterol ratio (-13.2%, -8.3%), BMD increased significantly in the total hip (1.66% for RLX60) and ultradistal radius (2.92%, 2.50%). There were nonsignificant trends toward increases over controls in BMD for lumbar spine, total body, and total hip (for RLX120), Using a >15% cutoff definition, raloxifene had no effect on incident fractures, but using a >30% cutoff there was a dose-related reduction (p = 0.047), We conclude that raloxifene therapy is,well tolerated, reduces serum lipids, and does not stimulate the uterus or breasts, It has beneficial effects on bone, although, under the conditions of this study, these appear to be of a smaller magnitude than have been reported with estrogen therapy.
引用
收藏
页码:1747 / 1754
页数:8
相关论文
共 26 条
  • [1] Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits
    Bjarnason, NH
    Haarbo, J
    Byrjalsen, I
    Kauffman, RF
    Christiansen, C
    [J]. CIRCULATION, 1997, 96 (06) : 1964 - 1969
  • [2] RALOXIFENE (LY139481 HCL) PREVENTS BONE LOSS AND REDUCES SERUM-CHOLESTEROL WITHOUT CAUSING UTERINE HYPERTROPHY IN OVARIECTOMIZED RATS
    BLACK, LJ
    SATO, M
    ROWLEY, ER
    MAGEE, DE
    BEKELE, A
    WILLIAMS, DC
    CULLINAN, GJ
    BENDELE, R
    KAUFFMAN, RF
    BENSCH, WR
    FROLIK, CA
    TERMINE, JD
    BRYANT, HU
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (01) : 63 - 69
  • [3] CLARKSON TB, 1997, OSTEOPOROS INT S1, V7, pS52
  • [4] THE USE OF ESTROGENS AND PROGESTINS AND THE RISK OF BREAST-CANCER IN POSTMENOPAUSAL WOMEN
    COLDITZ, GA
    HANKINSON, SE
    HUNTER, DJ
    WILLETT, WC
    MANSON, JE
    STAMPFER, MJ
    HENNEKENS, C
    ROSNER, B
    SPEIZER, FE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (24) : 1589 - 1593
  • [5] TAMOXIFEN - PANACEA OR PANDORA BOX
    DAVIDSON, NE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (13) : 885 - 886
  • [6] Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
    Delmas, PD
    Bjarnason, NH
    Mitlak, BH
    Ravoux, AC
    Shah, AS
    Huster, WJ
    Draper, M
    Christiansen, C
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (23) : 1641 - 1647
  • [7] Draper MW, 1996, J BONE MINER RES, V11, P835
  • [8] Treatment of postmenopausal osteoporosis
    Eastell, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (11) : 736 - 746
  • [9] HORMONE-THERAPY TO PREVENT DISEASE AND PROLONG LIFE IN POSTMENOPAUSAL WOMEN
    GRADY, D
    RUBIN, SM
    PETITTI, DB
    FOX, CS
    BLACK, D
    ETTINGER, B
    ERNSTER, VL
    CUMMINGS, SR
    [J]. ANNALS OF INTERNAL MEDICINE, 1992, 117 (12) : 1016 - 1037
  • [10] THE EFFECT OF THE ANTIESTROGEN TAMOXIFEN ON BONE-MINERAL DENSITY IN NORMAL LATE POSTMENOPAUSAL WOMEN
    GREY, AB
    STAPLETON, JP
    EVANS, MC
    TATNELL, MA
    AMES, RW
    REID, IR
    [J]. AMERICAN JOURNAL OF MEDICINE, 1995, 99 (06) : 636 - 641